Media Center
Press Releases
16 Apr 18

Back to posts

Global immunology market to surpass $100 billion by 2023

The immunology therapeutics market was estimated to be $65.1 billion in 2016, and is expected to grow to $113 billion in 2023, at an impressive compound annual growth rate of 8.2%, according to business intelligence provider GBI Research. 

The company’s latest report: ‘Global Immunology Drugs Market to 2023’ states that immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5–7% of people in Western populations. Their increasing prevalence is a major driver for market growth. 

The market is dominated by biologic anti-TNF drugs, but many of these are losing their patent protection, allowing for biosimilar competition. To avoid competition, drugs with novel targets are now entering the market.

Philippa Salter, Analyst at GBI Research, explains: “The big blockbuster drugs that dominate the current market, such as Enbrel, Remicade and Rituxan, are facing or have recently faced patent expiry. This allows for biosimilar drugs to enter the market, creating competition and therefore eroding the revenue for the top immunology drugs over the forecast period.”

By the end of 2018 most of the patents will have expired for Enbrel, Remicade, and Rituxan, which currently account for three of the top four highest revenue generating drugs, and all three will see decreased revenue over the forecast period due to the marketing of biosimilars. There are several first-in-class drugs that have recently been approved, and several in late stage pipeline development with novel targets, that are expected to become blockbuster drugs over the forecast period, generating further market growth within immunology. 

Salter adds: “Many of the drugs that are expected to do well over the forecast period revenue are first-in-class drugs, with a move away from traditional anti-TNF inhibitors. In particular, there will be an increase in drugs targeting interleukins, such as Stelara, Actemra and Cosentyx.”

Information based on the GBI Research report: Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

-ENDS-

NOTES TO EDITORS

- Comments provided by Philippa Salter, Associate Analyst for GBI Research

- Information based on the GBI Research report: Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

ABOUT GBI RESEARCH

GBI Research is a market-leading provider of business intelligence reports,offering actionable data and forecasts based on the insights of key industry leaders to ensure you stayup-to-date with the latest emerging trends in your markets.

For further details, please Contact Us.

Latest Press Releases

Close

Send this to a colleague

I have read and accept terms and conditions and privacy policy

Cancel